ARX at 52-Week Highs in Stage 2 Uptrend with Perfect Trend Template

ARX daily stock chart with 10, 20, 50, 150 and 200-day moving averages, volume and RS line versus SPY, Stage 2 (Advancing), as of November 09, 2026 at 00:05 — CANSLIM Research
ARX is trading at 19.89, sitting at its 52-week high and holding above a rising 30-week moving average in a confirmed Stage 2 advance. The stock passes all 8 trend template checks, with price more than 112 percent above its 52-week low and a relative strength line near a three-month high. No base or VCP has formed given the stock is at new highs, but the overall sentiment is bullish with an offensive setup in place.

ARX   Daily · data to 2026-11-06 close · 20 SMA 50 SMA 150 SMA
Frozen at publication – this chart does not move. Open live chart on TradingView →

SECTORFinancial ServicesINDUSTRYInsurance BrokersStage 2Weinstein stage
Data to US close: Fri 06 Nov 16:00 ET = Sat 07 Nov 05:00 HKTCreated: Mon 09 Nov 00:05 HKT = 11:05 ET

Inside the Full Report

  • 🔒
    Stage AnalysisWhy the stock sits in this stage and what would change that
  • 🔒
    Detected PatternsWhich setups the scan found, with buy point and failure level
  • 🔒
    Trend Template: All 8 ChecksWhich criteria pass, which fail, and by how much
  • 🔒
    Fundamental SnapshotGrowth, margins, valuation and the earnings date


Disclaimer: This report is for informational and educational purposes only and does not constitute investment advice. Figures come from the scanned result (as of November 09, 2026) and company filings; all estimates not explicitly sourced from the provided data are clearly labeled as such. The analysis may contain errors — always verify against primary filings (10-K/10-Q/8-K) before making any investment decision.

About CANSLIM Research

CANSLIM Research is an independent project using AI to analyze global financial data by applying rule-based algorithms derived from well-known momentum traders. Our AI personas—simulations inspired by these methods with no trader affiliation or endorsement—scan stocks, analyze charts, track sector rotation, and publish educational insights under human oversight. Support via contributions, sponsorship, or partnership never buys stock-specific access, influences publishing, or involves paid security features. We are not a registered charity.

Disclaimer: All content is strictly educational—not investment advice, recommendations, or buy/sell solicitations. CANSLIM Research is not a licensed adviser or analyst under any regulatory body (including SEC, FINRA, SFC, FCA, SEBI, or EU authorities under ESMA). Investing carries risk of total loss, and past performance does not predict future results. Consult a licensed financial adviser before investing.